Advertisement
Screener

OLEMA PHARMACEUTICALS, INC. (OLMA) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

OLEMA PHARMACEUTICALS, INC. Cash Flow Breakdown

Cash flow breakdown shows where OLEMA PHARMACEUTICALS, INC.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $146.72M went out.
  • Fiscal year ended 2025-12-31: from investing, $155.76M went out.
  • Fiscal year ended 2025-12-31: from financing, $211.30M came in.
  • Fiscal year ended 2025-12-31: change in cash, $91.18M went out.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingCommercial paperNew shares soldNot split outChange in cash
2025-12-31-$146.72M-$155.76M$3.00M$8.39M$199.91M*-$91.18M
2024-12-31-$104.35M-$93.53M$1.67M$267.15M*$70.94M
2023-12-31-$83.73M-$4.85M$2.63M$130.79M*$44.84M
2022-12-31-$82.06M$91.48M$146.00K$9.89M
2021-12-31-$50.69M-$275.44M$670.00K$721.00K*-$324.74M
2020-12-31-$19.87M-$56.00K$641.00K$357.76M*$338.48M
2019-12-31-$3.08M-$3.08M

Each quarter (3 month)

Quarter endRunning the businessFrom investingCommercial paperStaff share taxNew shares soldNot split outChange in cash
2026-06-30-$45.90M*$40.84M*-$4.19M*$5.30M*
2026-03-31-$45.99M$4.53M-$4.41M$8.43M$41.68M*$4.25M
2025-12-31-$38.33M*-$162.18M*$0.00*$7.88M*$205.67M*
2025-09-30-$34.53M*$17.27M*$0.00*$41.00K*
2025-06-30-$29.88M*$34.23M*$234.00K*-$2.75M*
2025-03-31-$43.98M-$45.08M$236.00K-$88.84M
2024-12-31-$26.28M*-$114.42M*$590.00K*$243.71M*
2024-09-30-$27.02M*$45.92M*$92.00K*
2024-06-30-$27.55M*-$4.88M*$69.00K*$15.54M*
2024-03-31-$23.50M-$20.14M$920.00K$7.90M*-$34.82M
2023-12-31-$18.48M*-$30.91M*$208.00K*
2023-09-30-$22.74M*-$25.44M*$869.00K*$129.76M*
2023-06-30-$22.12M*$14.11M*$1.33M*$711.00K*
2023-03-31-$20.39M$37.39M$220.00K$17.22M
2022-12-31-$19.71M*$16.34M*$0.00*
2022-09-30-$17.99M*$20.16M*$106.00K*
2022-06-30-$26.46M*$29.41M*$7.00K*
2022-03-31-$17.90M$25.57M$33.00K$7.70M
2021-12-31-$18.60M*$6.00M*$483.00K*
2021-09-30-$12.10M*-$12.78M*$57.00K*
2021-06-30-$8.90M*$10.93M*
2021-03-31-$11.08M-$279.58M-$290.67M
2020-12-31-$9.01M*-$51.00K*$1.00K*$219.79M*
2020-09-30-$7.54M*$10.00K*$84.87M*
2020-06-30-$1.18M*-$6.00K*$23.75M*
2020-03-31-$2.14M-$9.00K$29.99M*$27.84M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aclaris Therapeutics, Inc. (ACRS)United States$0.792B-9.78
Wave Life Sciences, Inc. (WVE)$0.780B-5.56
GERON CORP (GERN)United States$0.803B-12.14
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78
GYRE THERAPEUTICS, INC. (GYRE)United States$0.818B-24.71
LEXICON PHARMACEUTICALS, INC. (LXRX)United States$0.823B-17.48
Obsidian Therapeutics, Inc. (OBX)United States$0.829B
Faeth Therapeutics, Inc. (FTH)United States$0.750B
Immix Biopharma, Inc. (IMMX)United States$0.837B-18.44
Avalo Therapeutics, Inc. (AVTX)United States$0.842B-9.74